TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31469914
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of micro-needling (MN) and 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in Group-C (17 patients)
Study: 25794468
Drug: Weekly bisphosphonate
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly bisphosphonate (alendronate or risedronate)
Study: 25794468
Drug: Monthly bisphosphonate
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly bisphosphonate (minodronate)
Study: 23096041
Drug: Adaptol, 25-35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptol, 25-35 mg/kg for 1-3 months
Study: 10228375
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (applied to contralateral sites)
Study: 7699214
Drug: Dexamethasone (DXM,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (DXM, 1 mg orally overnight)
Study: 7699214
Drug: Loperamide (LOP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (LOP, 16 mg orally)
Study: 2740833
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (5 mg Folacin) for 1 year
Study: 30851062
Drug: evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: evolocumab 140 mg every 2 weeks (Q2W)
Study: 30851062
Drug: evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: evolocumab 420 mg monthly (QM)
Study: 15201943
Drug: Anakinra (interleukin-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (interleukin-1 receptor antagonist)
Study: 9035511
Drug: Nucleus CMP
Normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleus CMP forte (dysodic cytidinmonophosphate 5 mg, trisodic uridintriphosphate 3 mg, hydroxicobalamin 2 mg) tid for six months
Study: 3866536
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg slow-release pentoxifylline tablets ('Trental 400') twice a day for one week, followed by three times daily for seven weeks
Study: 1837120
Drug: LO‐Tact‐1 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LO‐Tact‐1 (10 mg i.v. per day) with cyclosporin (8 mg/kg/day), low‐dose steroids (1/2 mg/kg/day), and azathioprine (1 mg/kg/day starting at day 45)
Study: 1837120
Drug: Cyclosporin, high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin, high‐dose steroids (2 mg/day at day 1), and a 14‐day course of polyclonal horse antilymphocyte globulins (ALG)
Study: 1837120
Drug: LO‐Tact‐1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LO‐Tact‐1 treatment
Study: 1837120
Drug: Cyclosporin, high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin, high‐dose steroids, and ALG
Study: 82030
Drug: Continuous levamisole
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous levamisole treatment
Study: 82030
Drug: Intermittent levamisole
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent levamisole treatment
Study: 31160080
Drug: Polytetrafluoroethylene strips
Normalized name: polytetrafluoroethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polytetrafluoroethylene strips as an adjunct to epinephrine‐impregnated gauze (test group, n = 15)
Study: 28452620
Drug: Intensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive periodontal therapy for 4 weeks
Study: 22085402
Drug: 0.1 mol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mol/L hydrochloric acid infusion
Study: 19308439
Drug: Thermal water
Normalized name: thermal water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal water with negligible radon content (6 Bq/l) for 15 days
Study: 17308218
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 15 mg/day
Study: 11577835
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg alteplase (15 mg as bolus, followed by an infusion of 35 mg over 60 min) plus tirofiban (0.4 mcg/kg/min for 30 min followed by an infusion of 0.1 mcg/kg/min for 3 days)
Study: 3323074
Drug: Ceftazidime 3
Normalized name: ceftazidime 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 3 perioperative 1 g intramuscular doses every 6 h (group B)
Study: 24834773
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with Pru p 3-enriched peach extract
Study: 18457717
Drug: Percutaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous treatment with distal protection
Study: 15670265
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and biofeedback (BF) therapy
Study: 12200980
Drug: 6 mg/kg/24
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg/24 h ferrous sulphate given orally for 3 months
Study: 22587485
Drug: LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED therapy
Study: 22587485
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation and laser therapy
Study: 22587485
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation and LED therapy
Study: 17724210
Drug: Topical clonidine
Normalized name: clonidine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clonidine
Study: 15038091
Drug: LPZ(60 mg/d)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ(60 mg/d) alone
Study: 15038091
Drug: LPZ(60 mg/d)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ(60 mg/d) with CAM(400 mg/d) and AMPC(1,500 mg/d)
Study: 15038091
Drug: LPZ(60 mg/d)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ(60 mg/d) with CAM(800 mg/d) and AMPC(1,500 mg/d)
Study: 7982254
Drug: Ampicillin/sulbactam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam (1 to 2 g ampicillin and 0.5 to 1 g sulbactam, administered intravenously once every 6 hours)
Study: 2600246
Drug: 10-week group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-week group treatment program
Study: 31518550
Drug: Normal placental
Normalized name: human placental tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal placental growth factor (>100 pg/mL)
Study: 31518550
Drug: Placental growth
Normalized name: RECOMBINANT HUMAN PLACENTAL GROWTH FACTOR
DrugBank: Recombinant human placental growth factor (PLGF-131) (DB18586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placental growth factor ≤100 pg/mL
Study: 31518550
Drug: Placental growth
Normalized name: RECOMBINANT HUMAN PLACENTAL GROWTH FACTOR
DrugBank: Recombinant human placental growth factor (PLGF-131) (DB18586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placental growth factor <12 pg/mL
Study: 31518550
Drug: Placental growth
Normalized name: RECOMBINANT HUMAN PLACENTAL GROWTH FACTOR
DrugBank: Recombinant human placental growth factor (PLGF-131) (DB18586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placental growth factor 12-100 pg/mL
Study: 24960095
Drug: Deep oscillation
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep oscillation treatment applied for at least one week following the operation.
Study: 24960095
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no deep oscillation treatment).
Study: 14987329
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 60 mg orlistat
Study: 14987329
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 120 mg orlistat
Study: 29991700
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with autologous stem cell transplantation (ASCT)
Study: 2736420
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg etomidate (group II; n = 6)
Study: 2736420
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg etomidate (group III; n = 6)
Study: 22177541
Drug: Pre-operative fluid
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative fluid loading with 25 ml/kg of Ringer's solution in the six hours before surgery
Study: 19818722
Drug: 11-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-valent pneumococcal protein D conjugate vaccine
Study: 10489822
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg
Study: 16513447
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of telithromycin and montelukast
Study: 15568664
Drug: Complex drug
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex drug and laser therapy
Study: 9381027
Drug: Cognex (donepezil)
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cognex (donepezil) treatment, specific dosage and duration not mentioned
Study: 1948791
Drug: Inhaled PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhaled PGE2 (100 micrograms)
Study: 29536252
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% administered for local wound infiltration
Study: 9503259
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment (24 +/- 15 months prior to study)
Study: 9503259
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment (6 weeks)
Study: 3732427
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of fenoterol in powder form
Study: 3732427
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of fenoterol in MDI form
Study: 28188479
Drug: Normal weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal weight control group (no treatment)
Study: 8351679
Drug: Ethyl biscoumacetate
Normalized name: Ethyl biscoumacetate
DrugBank: Ethyl biscoumacetate (DB08794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl biscoumacetate (300 mg) alone
Study: 26437311
Drug: 10 session
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 session cognitive behavioral therapy (IPaViT‐CBT) group intervention
Study: 24176784
Drug: Kundalini Yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kundalini Yoga Therapy
Study: 24176784
Drug: Yoga Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga Therapy Adapted for Older Veterans
Study: 24176784
Drug: Yoga Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga Therapy
Study: 16542200
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide 54 mcg
Study: 16542200
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 40 mcg
Study: 10634377
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg tid)
Study: 19018143
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the dose of low-, medium-, and high-potency statins
Study: 2202901
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of beta carotene per day
Study: 29409133
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg and 150 mg
Study: 17668973
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus 25% metronidazole gel
Study: 2452564
Drug: Prourokinase (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prourokinase (7.5 mg bolus + 66.5 mg infusion over 60 minutes)
Study: 2452564
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prourokinase (3.7 mg bolus + 250,000 IU urokinase + 44.3 mg prourokinase)
Study: 31617568
Drug: 2-dose (2D)
Normalized name: Hep A, ped/adol, 2 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose (2D) quadrivalent HPV vaccine
Study: 31617568
Drug: 3-dose (3D)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-dose (3D) quadrivalent HPV vaccine in women aged 16-26
Study: 18188711
Drug: rhEPOalpha treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPOalpha treatment (n = 50)
Study: 18188711
Drug: EPO receptor
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO receptor protein expression
Study: 12612902
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus TIPS
Study: 8740106
Drug: Miconazole oral
Normalized name: miconazole Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole oral gel (Daktar, Janssen)
Study: 8740106
Drug: Nystatin oral
Normalized name: nystatin Oral Tablet
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin oral gel (Candio‐Hermal)
Study: 8740106
Drug: Nystatin oral
Normalized name: nystatin Oral Tablet
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin oral gel (Lederlind)
Study: 1831972
Drug: Cognitive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive treatment (with or without relaxation training)
Study: 6129364
Drug: Reduced daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced daily salt intake from 192 mmol to 77 mmol
Study: 11573752
Drug: Medical Nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Nutrition Therapy (MNT)
Study: 22261362
Drug: Very accelerated
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very accelerated radiotherapy (64·8 Gy [1·8 Gy twice daily] in 3·5 weeks)
Study: 6614128
Drug: Neurodevelopmental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental treatment (NDT)
Study: 16495471
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 microg daily)
Study: 8873109
Drug: High-dose UL
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UL ECT (three times the threshold)
Study: 8873109
Drug: Low-dose UL
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose UL ECT (threshold)
Study: 1505422
Drug: Daily brushing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily brushing (96% reported brushing daily)
Study: 31650861
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement adherence
Study: 31409380
Drug: CNS-focused treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS-focused treatment program
Study: 31409380
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical and physical therapy care
Study: 22751874
Drug: Cholecalciferol (vitamin
Normalized name: cholecalciferol (vitamin D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (vitamin D3) 2000 IU daily
Study: 3313101
Drug: Azathioprine with
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine with steroids
Study: 22728026
Drug: nab-paclitaxel 150
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 150 mg/m(2) qw 3/4
Study: 17684468
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate and biotin combination (600 microg chromium as chromium picolinate and 2 mg biotin)
Study: 9577944
Drug: Intracoronary (IC)
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary (IC) enalaprilat (0.05 mg/min for 15 minutes)
Study: 9577944
Drug: Sublingual (SL)
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual (SL) captopril (25 mg)
Study: 8588830
Drug: Syncroner (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syncroner (2 puffs of 2 mg 4 times a day for two weeks)
Study: 8588830
Drug: Standard mouthpiece
Normalized name: BREATHING CIRCUIT W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard mouthpiece (2 puffs of 2 mg 4 times a day for two weeks)
Study: 46712
Drug: Progesterone-releasing devices
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone-releasing devices (various doses)
Study: 31038562
Drug: sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 100 mg per day + metformin + insulin glargine
Study: 31038562
Drug: voglibose 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: voglibose 0.2 mg three times daily + metformin + insulin glargine
Study: 16703733
Drug: Tadalafil dosing
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil dosing instructions
Study: 2884114
Drug: Fenoldopam mesylate
Normalized name: Fenoldopam Mesylate
DrugBank: Fenoldopam (DB00800)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenoldopam mesylate 100 mg under fed conditions
Study: 2884114
Drug: Fenoldopam 24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam 24-hour excretion under fed conditions
Study: 2884114
Drug: SK&F 87782
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK&F 87782 24-hour excretion under fed conditions
Study: 28874948
Drug: Electronic prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic prescriptions (E-prescriptions)
Study: 28874948
Drug: Handwritten prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handwritten prescriptions (HW)
Study: 26892359
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 1 mg/kg (MS)
Study: 9770938
Drug: Soaks and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soaks and daily dressing changes
Study: 1974071
Drug: Alpidem 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem 50 mg
Study: 2574502
Drug: Alpidem 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem 75 mg
Study: 2901120
Drug: Alpidem 50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem 50-150 mg/day for 3-4 weeks
Study: 26717970
Drug: Ultrasound-guided subacromial
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided subacromial corticosteroid injection
Study: 26717970
Drug: Blind subacromial
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind subacromial corticosteroid injection
Study: 30852837
Drug: Oxycodone (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (0.03 mg/kg)
Study: 28719554
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment with a figure‐of‐eight harness
Study: 25492411
Drug: 150 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 µg corifollitropin alfa
Study: 25829811
Drug: Atorvastatin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin group
Study: 17257455
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of paracetamol combined with 60 mg of pseudoephedrine
Study: 12734763
Drug: Trimipramine (300-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine (300-400 mg)
Study: 12734763
Drug: Perazine (450-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perazine (450-600 mg)
Study: 1478201
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) therapy for 12 weeks
Study: 1478201
Drug: Chronic LTG
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic LTG therapy
Study: 6233622
Drug: zimelidine, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: zimelidine, a serotonin re‐uptake inhibitor
Study: 6233622
Drug: imipramine, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipramine, a noradrenaline re‐uptake inhibitor
Study: 31884206
Drug: Doxofylline 400
Normalized name: Doxofylline 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxofylline 400 mg t.i.d. for one year
Study: 15569362
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg b.i.d. (group A)
Study: 2885190
Drug: Alfentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil infusion at 50 micrograms kg‐1 hr‐1
Study: 2885190
Drug: Alfentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil infusion at 100 micrograms kg‐1 hr‐1
Study: 2885190
Drug: Alfentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil infusion continued for two hours post-operatively at 20 micrograms kg‐1 hr‐1